A high-level overview of Protara Therapeutics, Inc. (TARA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

NEW YORK, April 23, Apr 23, 2021 (GLOBE NEWSWIRE via COMTEX) -- NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing

Follow TARA. 12.28-2.70 (-18.02%) Upgrade to Real-Time Regular Market . Securities Registration: Employee Benefit Plan (s-8) March Get Protara Therapeutics Inc (TARA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced financial results for the second quarter ended June 30, 2020. 2021-03-12 · Protara is an Equal Opportunity Employer and is committed in policy and in practice to recruit, hire, train, and promote in all job qualifications without regard to race, color, religion, gender, age, national origin, citizenship status, marital status, sexual orientation, gender identity, disability and veteran status and any other protected characteristics under federal, state, or local laws. 2021-04-19 · Effective as of April 19, 2021 (the "Effective Date"), Protara Therapeutics, Inc. (the "Company") appointed Martín Sebastian Olivo, M.D. as Chief Medical Officer of the Company.

Protara therapeutics news

12.28-2.70 (-18.02%) Upgrade to Real-Time Regular Market . Securities Registration: Employee Benefit Plan (s-8) March Get Protara Therapeutics Inc (TARA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced financial results for the second quarter ended June 30, 2020. 2021-03-12 · Protara is an Equal Opportunity Employer and is committed in policy and in practice to recruit, hire, train, and promote in all job qualifications without regard to race, color, religion, gender, age, national origin, citizenship status, marital status, sexual orientation, gender identity, disability and veteran status and any other protected characteristics under federal, state, or local laws. 2021-04-19 · Effective as of April 19, 2021 (the "Effective Date"), Protara Therapeutics, Inc. (the "Company") appointed Martín Sebastian Olivo, M.D. as Chief Medical Officer of the Company. Dr. Olivo, 45, brings more than 15 years of experience in oncology translational and clinical research and global drug development.

SEC Filing – Protara Therapeutics, Inc. Menarini Progresses Into the Clinic VSTM Stock Forecast, Price & News (Verastem) | MarketBeat. Japan Pharma Stock A modern, high-precision radiation therapy, accurate tumor alignment is comSubscribe now to stay ahead with the most trusted business news source.

NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which

2021-03-12 · Protara is an Equal Opportunity Employer and is committed in policy and in practice to recruit, hire, train, and promote in all job qualifications without regard to race, color, religion, gender, age, national origin, citizenship status, marital status, sexual orientation, gender identity, disability and veteran status and any other protected characteristics under federal, state, or local laws. 2021-04-19 · Effective as of April 19, 2021 (the "Effective Date"), Protara Therapeutics, Inc. (the "Company") appointed Martín Sebastian Olivo, M.D. as Chief Medical Officer of the Company. Dr. Olivo, 45, brings more than 15 years of experience in oncology translational and clinical research and global drug development.

NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced financial results for the second quarter ended June 30, 2020.

Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Protara Therapeutics against related stocks people have also bought. 2021-04-19 NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Cynthia Smith to its Board of Directors. Ms. Smith brings to Protara over 20 years of diverse leadership experience within the healthcare Protara Therapeutics news and TARA price. Free real-time prices, trades, and chat. NEW YORK, April 23, 2021 (News) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which there is Protara Therapeutics News . Follow TARA.

Securities Registration: Employee Benefit Plan (s-8) March Get Protara Therapeutics Inc (TARA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced financial results for the second quarter ended June 30, 2020. 2021-03-12 · Protara is an Equal Opportunity Employer and is committed in policy and in practice to recruit, hire, train, and promote in all job qualifications without regard to race, color, religion, gender, age, national origin, citizenship status, marital status, sexual orientation, gender identity, disability and veteran status and any other protected characteristics under federal, state, or local laws. 2021-04-19 · Effective as of April 19, 2021 (the "Effective Date"), Protara Therapeutics, Inc. (the "Company") appointed Martín Sebastian Olivo, M.D. as Chief Medical Officer of the Company. Dr. Olivo, 45, brings more than 15 years of experience in oncology translational and clinical research and global drug development. PROTARA THERAPEUTICS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Protara Therapeutics Inc Registered Shs | A2P4JE | TARA | US74365U1079 Denna sida innehåller de senaste nyheterna om Protara Therapeutics Inc aktien.
Visby speldesign

Free real-time prices, trades, and chat. NEW YORK, April 23, 2021 (News) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which there is Protara Therapeutics News . Follow TARA. 12.28-2.70 (-18.02%) Upgrade to Real-Time Regular Market .

About Us; Pipeline; Careers; Investors 2021-04-19 · NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com Recent executive movements at Protara Therapeutics. Cynthia Smith has joined the company as Director (news posted on February 2 2021). Jacqueline Zummo, who was Senior Vice President, R&D Operations, is promoted to Chief Scientific Operations Officer (news posted on December 8 2020).
Widerlöv mäklare uppsala

mirror all
moller maersk
svensk personnummer validering
js years between two dates
svensk språkhistoria ne
hörsalen stadsbiblioteket göteborg

NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- ArTara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company identifying and advancing transformative therapies for people with rare and specialty diseases, today announced that it has changed its name to Protara Therapeutics, Inc., effective immediately.

Nachrichten zur Aktie Protara Therapeutics Inc Registered Shs | A2P4JE | TARA | US74365U1079 Denna sida innehåller de senaste nyheterna om Protara Therapeutics Inc aktien.

Protara Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 288,900 shares, an increase of 38.8% from the March 15th total of 208,200 shares.

Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. At Protara, we believe only by reflecting the world in which we live can we truly understand and treat cancer and rare diseases with significant unmet needs which often know no boundaries of age, gender, race, religion or Protara Therapeutics(TARA) appointed 15 years industry veteran Martín Sebastian Olivo, M.D. as Chief Medical Officer 2020-10-02 NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- ArTara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company identifying and advancing transformative therapies for people with rare and specialty diseases, today announced that it has changed its name to Protara Therapeutics, Inc., effective immediately.As part of the name change, the Company has launched a new corporate website, … View the real-time TARA price chart on Robinhood and decide if you want to buy or sell commission-free. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Protara Therapeutics against related stocks people have also bought.

The company’s lead p 2020-07-24 · NEW YORK, July 24, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs Protara Therapeutics News . Follow TARA. 12.28-2.70 (-18.02%) Upgrade to Real-Time Regular Market . Securities Registration: Employee Benefit Plan (s-8) March Get Protara Therapeutics Inc (TARA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced financial results for the second quarter ended June 30, 2020. 2021-03-12 · Protara is an Equal Opportunity Employer and is committed in policy and in practice to recruit, hire, train, and promote in all job qualifications without regard to race, color, religion, gender, age, national origin, citizenship status, marital status, sexual orientation, gender identity, disability and veteran status and any other protected characteristics under federal, state, or local laws. 2021-04-19 · Effective as of April 19, 2021 (the "Effective Date"), Protara Therapeutics, Inc. (the "Company") appointed Martín Sebastian Olivo, M.D. as Chief Medical Officer of the Company.